case_images: PMC11324272_01
case_images: HE staining of the prostate needle biopsy specimen. Gleason score 5 + 5 = 10, adenocarcinoma. Pattern 5 adenocarcinoma consisting mainly of enriched foci containing seal cell-like carcinoma cells.
case_images: cro-2024-0017-0001-540419_F01.jpg
case_images: PMC11324272_01_cro-2024-0017-0001-540419_F01.jpg
case_images: F1
case_images: A prostate needle biopsy revealed adenocarcinoma with a Gleason score of 5 + 5 = 10 (Fig. 1).
case_images: Bone scintigraphy findings in initial (a), post-1st-line treatment (b), pre-olaparib (c), and post-olaparib (d) status.
case_images: cro-2024-0017-0001-540419_F02.jpg
case_images: PMC11324272_01_cro-2024-0017-0001-540419_F02.jpg
case_images: F2
case_images: Bone scintigraphy and computed tomography (CT) revealed bone metastasis without visceral metastasis (Fig. 2a). At 4 months after the initial treatment, the patient's PSA level decreased to 0.144 ng/mL, and both the primary and metastatic tumors shrank (Fig. 2b). His PSA level decreased, and CT showed that the LNs had decreased in size (Fig. 2c, d, 3, 4).
case_images: Axial non-contrast CT. The pre-pembrolizumab (a) and post-pembrolizumab (b) statuses.
case_images: cro-2024-0017-0001-540419_F03.jpg
case_images: PMC11324272_01_cro-2024-0017-0001-540419_F03.jpg
case_images: F3
case_images: His PSA level decreased, and CT showed that the LNs had decreased in size (Fig. 2c, d, 3, 4).
case_images: Clinical course.
case_images: cro-2024-0017-0001-540419_F04.jpg
case_images: PMC11324272_01_cro-2024-0017-0001-540419_F04.jpg
case_images: F4
case_images: His PSA level decreased, and CT showed that the LNs had decreased in size (Fig. 2c, d, 3, 4).